Expression and selective activation of somatostatin receptor subtypes induces cell cycle arrest in cancer cells
Authors:
Open Access
- 28 November 2018
- journal article
- research article
- Published by Spandidos Publications in Oncology Letters
- Vol. 17 (2) , 1723-1731
Abstract
Somatostatin receptors (SSTRs) are G‑protein‑coupled plasma membrane receptors that have been determined to be expressed in normal and cancer tissues. Activation of SSTRs frequently results in inhibition of cell proliferation and therefore somatostatin analogues (SSAs) have been used in cancer treatment. However, the variable outcomes of SSA treatment were considered to be the consequences of loss‑of‑expression of SSTRs and/or subtype‑specific effects. In the present study, the patterns of SSTR expression in 160 breast cancer tissues were investigated, and the mechanisms of SSTR activation and the influence on cell proliferation were further characterized. The expression levels of SSTR1‑5 were determined using immunohistology. Hemagglutinin‑SSTR1 and MYC‑SSTR4 were transiently overexpressed in MDA‑MB‑435S cells, and the potential receptor dimerization was determined using immunofluorescence and co‑immunoprecipitation. The influence of SSTR1 and SSTR4 expression/activation on cell proliferation was monitored using flow cytometry. The results demonstrated that all five SSTR subtypes were expressed at variable levels in tumor tissues, with the highest positive expression instance being determined for SSTR1 and SSTR4, with positive expression levels in 90.0 and 71.3% of tumor tissues, respectively. Immunofluorescence and co‑immunoprecipitation revealed SSTR1/SSTR4 heterodimerization, which was increased in response to receptor activation using the subtype‑specific SSA L‑803087. The translocation of SSTR1/SSTR4 dimers into the cytoplasm upon receptor activation was also observed. Additionally, it was identified using flow cytometry that co‑expression and activation of SSTR1 and SSTR4 in MDA‑MB‑435S cells resulted in a decreased proportion of S‑phase cells. The results of the present study revealed that SSTR1 and SSTR4 are the most frequently expressed SSTR subtypes in breast cancer, and that the cell cycle arrest was mediated by SSTR1/SSTR4 dimerization/activation.Keywords
This publication has 43 references indexed in Scilit:
- Coexpression of human somatostatin receptor-2 (SSTR2) and SSTR3 modulates antiproliferative signaling and apoptosisJournal of Molecular Signaling, 2012
- Comparative evaluation of the modified Scarff-Bloom-Richardson grading system on breast carcinoma aspirates and histopathologyCytojournal, 2012
- The adaptor protein p62/SQSTM1 in osteoclast signaling pathwaysJournal of Molecular Signaling, 2012
- Monoclonal Antibodies against the Human Somatostatin Receptor Subtypes 1–5: Development and Immunohistochemical Application in Neuroendocrine TumorsNeuroendocrinology, 2011
- Receptor specific crosstalk and modulation of signaling upon heterodimerization between β1-adrenergic receptor and somatostatin receptor-5Cellular Signalling, 2011
- Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancyCancer Imaging, 2010
- Somatostatin/somatostatin receptor signalling: Phosphotyrosine phosphatasesMolecular and Cellular Endocrinology, 2008
- Biology of somatostatin in breast cancerMolecular and Cellular Endocrinology, 2008
- MDA-MB-435 cells are derived from M14 Melanoma cells––a loss for breast cancer, but a boon for melanoma researchBreast Cancer Research and Treatment, 2006
- Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1–5 and correlation with receptor protein expression and tumor pathologyBreast Cancer Research and Treatment, 2005